BioCentury
ARTICLE | Clinical News

Polyphor reports Phase Ib data for breast cancer candidate

March 30, 2018 5:57 PM UTC

Polyphor Ltd. (Allschwill, Switzerland) reported data from an open-label, dose-escalation Phase Ib trial in 54 women with previously treated HER2-negative, CXC chemokine receptor 4 (CXCR4; NPY3R)-positive metastatic breast cancer showing that IV balixafortide (POL6326) plus Halaven eribulin led to an overall response rate (ORR) of 29.6%, including 16 partial responses, plus 25 cases of stable disease. Median progression-free survival (PFS) was 4.5 months.

In an expansion cohort of 24 patients who received 5.5 mg/kg balixafortide -- the highest dose tested -- plus Halaven, the combination led to an ORR of 37.5%, including nine partial responses, and a median PFS of 6.2 months. Data were presented at the European Breast Cancer Conference in Barcelona...

BCIQ Company Profiles

Polyphor AG